The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

HER2-Negative Breast Cancer MORE >>

An accelerated approval has been granted by the FDA for the combination of atezolizumab and nab-paclitaxel as a frontline treatment for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.